Pancreatic cancer remains one of the most aggressive forms of the disease, with survival rates still alarmingly low, but recent advances in experimental treatments are offering cautious hope to patients and researchers.
According to studies, only around one in 10 people diagnosed with Pancreatic cancer survive more than five years, and incidence rates are rising globally, particularly among younger adults. The disease is projected to become the second deadliest cancer in developed countries, behind lung cancer.
Despite decades of limited progress, researchers say increased funding and scientific focus in recent years are beginning to yield results. Patrick Mehlen of the Leon Berard Cancer Centre said there had not been “any medical progress for 40 years,” but added that growing investment over the past decade is now making a “real difference.”
One of the most closely watched developments is an experimental drug called daraxonrasib, developed by Revolution Medicines. The treatment targets the KRAS protein, which plays a key role in tumour growth.
In recent trial results, around half of patients taking the drug survived more than 13 months — roughly double the survival time of those receiving standard chemotherapy. While not a cure, researchers say the improvement is significant for a cancer known for its rapid progression.
Former US senator Ben Sasse, who was diagnosed with stage-four pancreatic cancer, described the impact of the drug in personal terms. “In mid-December I got a three-to-four month life expectancy,” the 54-year-old said. After starting treatment, he added: “I’m doing a heck of a lot better than I was doing at Christmas.” He cautioned, however, that it is “a nasty drug,” citing severe side effects.
Revolution Medicines has indicated it plans to seek regulatory approval in the United States, with further results from its phase 3 trial expected to be presented at an upcoming oncology conference in Chicago.
Alongside drug development, scientists are also exploring new approaches aimed at improving the effectiveness of existing treatments. Research published in the journal Nature examined an antibody treatment known as NP137, which is designed to prevent cancer cells from becoming resistant to therapies such as chemotherapy.
In an early-stage trial involving 43 patients, the treatment extended survival by several months compared to typical outcomes. “We’re giving people an average of six months more — which is significant for this disease,” said Mehlen, who supervised the study. Larger trials are planned to further evaluate its effectiveness.
Another promising avenue is the development of a cancer vaccine using messenger RNA technology, pioneered during the Covid-19 pandemic. The vaccine, created by BioNTech and Genentech, aims to stimulate the immune system to target cancer cells.
In a phase 1 trial involving 16 patients, half showed an immune response to the vaccine, with seven of those patients still alive six years later. By contrast, survival rates were significantly lower among those who did not respond.
Researchers caution that early-stage trials are primarily designed to assess safety rather than effectiveness, and further studies will be required. However, the findings mark a significant step forward in efforts to improve outcomes for one of the world’s deadliest cancers.